These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37679571)

  • 1. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA.
    Li B; Jiang AY; Raji I; Atyeo C; Raimondo TM; Gordon AGR; Rhym LH; Samad T; MacIsaac C; Witten J; Mughal H; Chicz TM; Xu Y; McNamara RP; Bhatia S; Alter G; Langer R; Anderson DG
    Nat Biomed Eng; 2023 Sep; ():. PubMed ID: 37679571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
    Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
    ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
    Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
    Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
    Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
    J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles.
    Wang J; Zhang Y; Dong S; Zha W; Liu C; Wang Y; Jiang Y; Xing H; Li X
    Int J Pharm; 2023 Jul; 642():123155. PubMed ID: 37402442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
    Takanashi A; Pouton CW; Al-Wassiti H
    Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery.
    Long J; Yu C; Zhang H; Cao Y; Sang Y; Lu H; Zhang Z; Wang X; Wang H; Song G; Yang J; Wang S
    Adv Healthc Mater; 2023 May; 12(13):e2202590. PubMed ID: 36716702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
    Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
    J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates.
    Suzuki Y; Miyazaki T; Muto H; Kubara K; Mukai Y; Watari R; Sato S; Kondo K; Tsukumo SI; Yasutomo K; Ito M; Tsukahara K
    Mol Ther Nucleic Acids; 2022 Dec; 30():226-240. PubMed ID: 36187052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines.
    Li Z; Zhang XQ; Ho W; Li F; Gao M; Bai X; Xu X
    ACS Nano; 2022 Nov; 16(11):18936-18950. PubMed ID: 36269150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.
    Elia U; Rotem S; Bar-Haim E; Ramishetti S; Naidu GS; Gur D; Aftalion M; Israeli M; Bercovich-Kinori A; Alcalay R; Makdasi E; Chitlaru T; Rosenfeld R; Israely T; Melamed S; Abutbul Ionita I; Danino D; Peer D; Cohen O
    Nano Lett; 2021 Jun; 21(11):4774-4779. PubMed ID: 34032435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of adjuvantation strategy of lipid squalene nanoparticles for enhancing the immunogenicity of a SARS-CoV-2 spike subunit protein against COVID-19.
    Ho HM; Huang CY; Cheng YJ; Shen KY; Tzeng TT; Liu SJ; Chen HW; Huang CH; Huang MH
    Int J Pharm; 2021 Sep; 607():121024. PubMed ID: 34416331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
    Toyama K; Eto T; Takazawa K; Shimizu S; Nakayama T; Furihata K; Sogawa Y; Kumazaki M; Jonai N; Matsunaga S; Takeshita F; Yoshihara K; Ishizuka H
    Vaccine; 2023 Aug; 41(38):5525-5534. PubMed ID: 37586958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.
    Song JY; Choi WS; Heo JY; Lee JS; Jung DS; Kim SW; Park KH; Eom JS; Jeong SJ; Lee J; Kwon KT; Choi HJ; Sohn JW; Kim YK; Noh JY; Kim WJ; Roman F; Ceregido MA; Solmi F; Philippot A; Walls AC; Carter L; Veesler D; King NP; Kim H; Ryu JH; Lee SJ; Park YW; Park HK; Cheong HJ
    EClinicalMedicine; 2022 Sep; 51():101569. PubMed ID: 35879941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids.
    Chen K; Fan N; Huang H; Jiang X; Qin S; Xiao W; Zheng Q; Zhang Y; Duan X; Qin Z; Liu Y; Zeng J; Wei Y; Song X
    Adv Funct Mater; 2022 Sep; 32(39):2204692. PubMed ID: 35942272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
    Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
    Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
    Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
    J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid nanoparticle-based mRNA candidates elicit potent T cell responses.
    Zeng Y; Escalona-Rayo O; Knol R; Kros A; Slütter B
    Biomater Sci; 2023 Jan; 11(3):964-974. PubMed ID: 36537916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines.
    Swetha K; Kotla NG; Tunki L; Jayaraj A; Bhargava SK; Hu H; Bonam SR; Kurapati R
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.